ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 36725112

Heparan sulfate proteoglycans in cancer: Pathogenesis and therapeutic potential.

Yang H and 1 other. Adv Cancer Res, 2023. Cited by 19 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Heparan sulfate proteoglycans in cancer: Pathogenesis and therapeutic potential. Papers, record 36725112. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36725112

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Heparan sulfate proteoglycans in cancer: Pathogenesis and therapeutic potential.
PubMed
Journal
Adv Cancer Res
PubMed
Year
2023
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
19
iCite
Relative citation ratio, by iCite
2.04
iCite
Revised in PubMed
2026-01-27
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yang HHua
2Wang LLianchun

Source PubMed

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Heparan Sulfate ProteoglycansMajor topic
NeoplasmsMajor topic
Animals
Humans
Heparan Sulfate
Neovascularization, Pathologic
Cell Differentiation
Mammals

Source PubMed

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
RF1 AG069039NIA NIH HHSUnited StatesRF1AG069039PubMed and NIHNIH RePORTER
RF1 AG074289NIA NIH HHSUnited StatesRF1AG074289PubMed and NIHNIH RePORTER
U01 CA225784NCI NIH HHSUnited StatesU01CA225784PubMed and NIHNIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References242

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
121,411,633The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells.Mol Biol Cell2011https://conductscience.org/library/papers/21411633PubMed
228,734,894GLCE rs3865014 (Val597Ile) polymorphism is associated with breast cancer susceptibility and triple-negative breast cancer in Siberian population.Gene2017https://conductscience.org/library/papers/28734894PubMed
333,704,312Synthetic heparan sulfate ligands for vascular endothelial growth factor to modulate angiogenesis.Chem Commun (Camb)2021https://conductscience.org/library/papers/33704312PubMed
432,228,854GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab.Elife2020https://conductscience.org/library/papers/32228854PubMed
524,260,047The overexpression of glypican-5 promotes cancer cell migration and is associated with shorter overall survival in non-small cell lung cancer.Oncol Lett2013https://conductscience.org/library/papers/24260047PubMed
623,844,358Expression of syndecan-4 and correlation with metastatic potential in testicular germ cell tumours.Biomed Res Int2013https://conductscience.org/library/papers/23844358PubMed
721,556,932Expression of GPC3 protein and its significance in lung squamous cell carcinoma.Med Oncol2012https://conductscience.org/library/papers/21556932PubMed
820,807,646Endothelial heparan sulfate in angiogenesis.Prog Mol Biol Transl Sci2010https://conductscience.org/library/papers/20807646PubMed
930,197,623Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression.Front Endocrinol (Lausanne)2018https://conductscience.org/library/papers/30197623PubMed
109,008,168Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.Cell1997https://conductscience.org/library/papers/9008168PubMed

1 to 10 of 242

See all 242 references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.

PMIDTitleJournalYearIn PapersSource
42,714,551Priming Cells with Modulators of Cellular Signaling Ensures Enhanced Selectivity of HSPG-Specific Protein-Drug Conjugate Delivery.J Am Chem Soc2026https://conductscience.org/library/papers/42714551PubMed
42,509,832Proteoglycans as Molecular Regulators of Bone Metastasis: Extracellular Matrix Remodeling, Tumor-Bone Crosstalk, Dormancy, and Therapeutic Opportunities.Biomolecules2026https://conductscience.org/library/papers/42509832PubMed
42,066,072Pervasive enhanced transcription in inflammatory breast cancer tumors and PBMCs impacts RNA splicing and intronic RNAs in plasma.Sci Adv2026https://conductscience.org/library/papers/42066072PubMed
41,068,982The integration of single-cell and metabolomics reveals the increase of oxidative phosphorylation during the liver metastasis of colorectal cancer.Cancer Metab2025https://conductscience.org/library/papers/41068982PubMed
40,564,190Applications of Surface Plasmon Resonance in Heparan Sulfate Interactome Research.Biomedicines2025https://conductscience.org/library/papers/40564190PubMed
40,445,765Genomic analyses identify 15 risk loci and reveal HDAC2, SOX2-OT, and IGF2BP2 in a naturally occurring canine model of gastric cancer.Proc Natl Acad Sci U S A2025https://conductscience.org/library/papers/40445765PubMed
40,352,786A rare germline mutation reverses the suppressive effect of GPC5 thereby promoting lung adenocarcinoma development and tumorigenesis.Front Genet2025https://conductscience.org/library/papers/40352786PubMed
39,895,690Tumor-specific cytosol-penetrating antibodies for antigen- and TME-dependent intracellular cargo delivery.Mol Ther Oncol2025https://conductscience.org/library/papers/39895690PubMed
39,822,499Heparan sulfate 6-O-sulfotransferase 2 promotes gastric cancer progression by modulating the TGF-β/smad2/3 pathway.Am J Transl Res2024https://conductscience.org/library/papers/39822499PubMed
39,417,004Branched oncolytic peptides target HSPGs, inhibit metastasis, and trigger the release of molecular determinants of immunogenic cell death in pancreatic cancer.Front Mol Biosci2024https://conductscience.org/library/papers/39417004PubMed

1 to 10 of 13

See all 13 cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
SDC26,383PubTator's text mininghttps://conductscience.org/library/genes/6383

Source NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36725112

GET https://conductscience.org/api/papers/v1/36725112/references?page=2

API referenceFor AI assistants